Drugs /

masitinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
masitinib
Trade Name(s):
Masivet

Clinical Trials

View Clinical Trials for masitinib

Masitinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating masitinib, 1 is phase 3 (0 open).

KIT Expression is the most frequent biomarker inclusion criterion for masitinib clinical trials.

Gastrointestinal stromal tumor is the most common disease being investigated in masitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Masitinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating masitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Masivet, ab1010, masitinib, 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide, masatinib, 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide
Drug Categories [2]:
PTK2 (FAK) inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3, KIT, LCK, LYN, PDGFRA, PDGFRB, PTK2
NCIT ID [1]:
C79910

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.